While biologics are emerging as the standard of care for rheumatoid arthritis (RA), they continue to be compared to methotrexate frequently in health technology assessments (HTAs). We examined comparators used by HTA agencies for RA drugs, both tumor necrosis factor (TNF) drugs and disease-modifying, anti-rheumatic drugs (DMARDs), and compared each drug’s HTA decision to its European label.
We also assessed the change in comparator categories for RA drugs over time.
Our research analyzed NICE, HAS, IQWiG, HIS, and SMC HTAs published from 2005-2014. (The G-BA, IQWiG’s counterpart, did not review RA during this time frame.) These HTAs represent all of the RA HTAs published by these agencies during this time period.
See our analysis and conclusions in the full research brief.